FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135827145> ?p ?o ?g. }

• W3135827145 endingPage "962" @default.
• W3135827145 startingPage "961" @default.
• W3135827145 abstract "We read with interest the correspondence letter sent by Kow et al1 and referring to our recently published article about the incidence of CoronaVIrus Disease 19 (COVID-19) in severe asthmatics of our Severe Asthma Network in Italy (SANI) registry.2 We agree with the authors that several factors, such as the type and the degree of strictness of lockdown measures implemented, and the different distribution of comorbidities, can contribute to different incidences of COVID-19 among severe asthmatics in different countries. Our article is, so far, the published report with the largest number of severe asthmatics (more than 1500), properly diagnosed and managed by reference centres, studied for incidence of COVID-19 which resulted lower than expected, associated with asthma exacerbation only in a minority of patients, and with lower mortality rate compared to the Italian general population. On the other hand, in support of their hypothesis that severe asthma is associated with more severe course of COVID-19, Kow et al cited and commented a retrospective study by Chhiba et al3 in which patients with COVID-19 were stratified according to the presence of asthma, defined by means of a consistent International Classification of Disease, Tenth Revision (ICD-10) code in the electronic repository of health records; the ICD-10-based classification is a good strategy to mine asthma cases in a retrospective general population study, but it is likely to be affected by a high proportion of misdiagnosed cases, as misdiagnosis has been reported as quite frequent in asthma and chronic obstructive pulmonary disease (COPD).4 Miscoding and misdiagnosing chronic respiratory diseases may result, as recently described, in underestimation of higher risk of more severe course of COVID-19 in asthmatic patients only when associated with comorbid diagnosis of COPD.5 In our cohort, patients had a confirmed diagnosis of severe asthma by reference centres, and the risk of misdiagnosis was therefore minimized. Moreover, Chhiba et al did not found significant difference in risk of hospitalization or mortality due to COVID-19 in patients with or without asthma, even after adjusting for covariates or the level of asthma treatment. Similar findings have been published also by other authors6, 7 strengthening that asthma seems not to be a relevant risk factor for more frequent and worse clinical outcomes of COVID-19. Furthermore, the definition of asthma severity according to the level of anti-asthma therapy (from step 1 to step 5 of Global Initiative for Asthma—GINA guidelines) requires that all patients have been treated with the minimum dose of drugs able to maintain the asthma control, and this is seldom assessed in the general practice. Notably, we agree with Kow et al that further real-life studies, possibly on well-defined and properly diagnosed patients with asthma, are needed to confirm our and other authors’ findings. This will be particularly relevant considering, for example, that a recent large-scale study on patients who underwent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) testing reported that a particular phenotype of asthma (non-allergic asthma) confers a greater risk of susceptibility to SARS-CoV-2 infection and severe clinical outcomes of COVID-19.8 SANI is supported through unrestricted grants by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Genzyme. We are grateful to Silvia Rabotti, Concetta Sirena and the SANI staff for the invaluable work in managing the network. Enrico Heffler reports participation to advisory boards and personal fees from AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestlè Purina, Boheringer Ingelheim and Valeas, outside the submitted work. Marco Contoli reports grants from Chiesi, and University of Ferrara—Italy, and personal fees from Chiesi, AstraZeneca, Boehringer Ingelheim, Alk-Abello, GlaxoSmithKline, Novartis and Zambon, outside the submitted work. Alberto Papi reports grants, grants, personal fees and non-financial support from AstraZeneca and Menarini; grants, personal fees, non-financial support and other from Boehringer Ingelheim, Chiesi Farmaceutici and TEVA; personal fees, non-financial support and other from GlaxoSmithKline, Mundipharma, Zambon, Novartis and Sanofi/Regeneron; personal fees from Roche and Edmond Pharma; and grants from Fondazione Maugeri and Fondazione Chiesi, outside the submitted work. Claudia Crimi reports personal fees from Menarini. Stefano Centanni reports personal fees from GlaxoSmithKline, Novartis, Menarini SpA, and Guidotti-Malesci, and grants and personal fees from Chiesi SpA, AstraZeneca, Valeas and Boehringer Ingelheim, outside the submitted work. Pierluigi Paggiaro reports grants and personal fees from AstraZeneca, Chiesi, Novartis and Sanofi, and personal fees from GlaxoSmithKline, Guidotti, and Mundipharma, outside the submitted work. Francesco Blasi reports grants and personal fees from AstraZeneca, Chiesi, GSK, Pfizer and Insmed; grants from Bayer; and personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis and Zambon, outside the submitted work. Giorgio Walter Canonica reports grants as well as lecture or advisory board fees from: A. Menarini, Alk-Abello, Allergy Therapeutics, AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, GlaxoSmithKline, Hal Allergy, Mylan, Merck, Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes Greer, UCB pharma, Uriach Pharma, Valeas and Vibro Pharma. Giovanni Paoletti, Aikaterini Detoraki, Giacomo Malipiero, Luisa Brussino, Daniela Morrone, Marianna Padovani, Giuseppe Guida, Alberto Giovanni Gerli and Gianenrico Senna do not have any conflict of interest to report." @default.
• W3135827145 created "2021-03-15" @default.
• W3135827145 creator A5004487731 @default.
• W3135827145 creator A5011323669 @default.
• W3135827145 creator A5015580414 @default.
• W3135827145 creator A5019798684 @default.
• W3135827145 creator A5024772834 @default.
• W3135827145 creator A5026887019 @default.
• W3135827145 creator A5027824133 @default.
• W3135827145 creator A5030660777 @default.
• W3135827145 creator A5037297396 @default.
• W3135827145 creator A5042486591 @default.
• W3135827145 creator A5054951446 @default.
• W3135827145 creator A5069242481 @default.
• W3135827145 creator A5076382222 @default.
• W3135827145 creator A5078033835 @default.
• W3135827145 creator A5080326198 @default.
• W3135827145 creator A5090058981 @default.
• W3135827145 creator A5090792230 @default.
• W3135827145 date "2021-03-01" @default.
• W3135827145 modified "2023-09-27" @default.
• W3135827145 title "Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID‐19?" @default.
• W3135827145 cites W2884142172 @default.
• W3135827145 cites W3035033705 @default.
• W3135827145 cites W3046360701 @default.
• W3135827145 cites W3049115642 @default.
• W3135827145 cites W3091484297 @default.
• W3135827145 doi "https://doi.org/10.1111/all.14593" @default.
• W3135827145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8251003" @default.
• W3135827145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33675253" @default.
• W3135827145 hasPublicationYear "2021" @default.
• W3135827145 type Work @default.
• W3135827145 sameAs 3135827145 @default.
• W3135827145 citedByCount "3" @default.
• W3135827145 countsByYear W31358271452021 @default.
• W3135827145 countsByYear W31358271452022 @default.
• W3135827145 crossrefType "journal-article" @default.
• W3135827145 hasAuthorship W3135827145A5004487731 @default.
• W3135827145 hasAuthorship W3135827145A5011323669 @default.
• W3135827145 hasAuthorship W3135827145A5015580414 @default.
• W3135827145 hasAuthorship W3135827145A5019798684 @default.
• W3135827145 hasAuthorship W3135827145A5024772834 @default.
• W3135827145 hasAuthorship W3135827145A5026887019 @default.
• W3135827145 hasAuthorship W3135827145A5027824133 @default.
• W3135827145 hasAuthorship W3135827145A5030660777 @default.
• W3135827145 hasAuthorship W3135827145A5037297396 @default.
• W3135827145 hasAuthorship W3135827145A5042486591 @default.
• W3135827145 hasAuthorship W3135827145A5054951446 @default.
• W3135827145 hasAuthorship W3135827145A5069242481 @default.
• W3135827145 hasAuthorship W3135827145A5076382222 @default.
• W3135827145 hasAuthorship W3135827145A5078033835 @default.
• W3135827145 hasAuthorship W3135827145A5080326198 @default.
• W3135827145 hasAuthorship W3135827145A5090058981 @default.
• W3135827145 hasAuthorship W3135827145A5090792230 @default.
• W3135827145 hasBestOaLocation W31358271451 @default.
• W3135827145 hasConcept C120665830 @default.
• W3135827145 hasConcept C121332964 @default.
• W3135827145 hasConcept C126322002 @default.
• W3135827145 hasConcept C167135981 @default.
• W3135827145 hasConcept C187212893 @default.
• W3135827145 hasConcept C2776042228 @default.
• W3135827145 hasConcept C2777014857 @default.
• W3135827145 hasConcept C2779134260 @default.
• W3135827145 hasConcept C2908647359 @default.
• W3135827145 hasConcept C3008058167 @default.
• W3135827145 hasConcept C524204448 @default.
• W3135827145 hasConcept C61511704 @default.
• W3135827145 hasConcept C71924100 @default.
• W3135827145 hasConcept C99454951 @default.
• W3135827145 hasConceptScore W3135827145C120665830 @default.
• W3135827145 hasConceptScore W3135827145C121332964 @default.
• W3135827145 hasConceptScore W3135827145C126322002 @default.
• W3135827145 hasConceptScore W3135827145C167135981 @default.
• W3135827145 hasConceptScore W3135827145C187212893 @default.
• W3135827145 hasConceptScore W3135827145C2776042228 @default.
• W3135827145 hasConceptScore W3135827145C2777014857 @default.
• W3135827145 hasConceptScore W3135827145C2779134260 @default.
• W3135827145 hasConceptScore W3135827145C2908647359 @default.
• W3135827145 hasConceptScore W3135827145C3008058167 @default.
• W3135827145 hasConceptScore W3135827145C524204448 @default.
• W3135827145 hasConceptScore W3135827145C61511704 @default.
• W3135827145 hasConceptScore W3135827145C71924100 @default.
• W3135827145 hasConceptScore W3135827145C99454951 @default.
• W3135827145 hasFunder F4320307770 @default.
• W3135827145 hasFunder F4320307778 @default.
• W3135827145 hasIssue "3" @default.
• W3135827145 hasLocation W31358271451 @default.
• W3135827145 hasLocation W31358271452 @default.
• W3135827145 hasLocation W31358271453 @default.
• W3135827145 hasLocation W31358271454 @default.
• W3135827145 hasOpenAccess W3135827145 @default.
• W3135827145 hasPrimaryLocation W31358271451 @default.
• W3135827145 hasRelatedWork W1673187729 @default.
• W3135827145 hasRelatedWork W1957770986 @default.
• W3135827145 hasRelatedWork W1985426726 @default.
• W3135827145 hasRelatedWork W1994339424 @default.
• W3135827145 hasRelatedWork W2000416421 @default.
• W3135827145 hasRelatedWork W2081841698 @default.

• next